Haemonetics Story

HAE -- USA Stock

USD 125.24 4.16 3.21%

Macroaxis Story

While some traders are getting carried away by overanalyzing healthcare space, it is reasonable to digest Haemonetics against current market trends. As expected, Haemonetics is starting to reaffirm its true potential as shareholders are becoming more and more confident in the future outlook. The returns on the market and returns on Haemonetics appear slightly-related for the last few months. The appearance of sound basic indicators of the firm indicates a shorter-term price swing for shareholders of Haemonetics. Haemonetics is scheduled to announce its earnings today. The next earnings report is expected on the 4th of May 2021. The stock experiences an active upward rally.

Published over three weeks ago

View all stories for Haemonetics Corp | View All Stories

Should I shadow Haemonetics (NYSE:HAE) shareholders?

This firm's average rating is Buy from 6 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Haemonetics market sentiment investors' perception of the future value of Haemonetics. Let us look at a few aspects of Haemonetics technical analysis.

Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Haemonetics Corp. In general, we focus on analyzing Haemonetics Corp stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Haemonetics Corp's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Haemonetics Corp's intrinsic value. In addition to deriving basic predictive indicators for Haemonetics Corp, we also check how macroeconomic factors affect Haemonetics Corp price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Haemonetics Corp's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Haemonetics Corp in the context of predictive analytics.

Please note, it is not enough to conduct a financial or market analysis of a single entity such as Haemonetics Corp. Your research has to be compared to or analyzed against Haemonetics Corp's peers to derive any actionable benefits. When done correctly, Haemonetics Corp's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Haemonetics Corp.

How does Haemonetics Stands against Peers?

Analyzing Haemonetics Corp competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Haemonetics Corp across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.

Check out Haemonetics Corp Competition Details

How Haemonetics utilizes its cash?

To perform a cash flow analysis of Haemonetics Corp, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Haemonetics Corp is receiving and how much cash it distributes out in a given period. The Haemonetics Corp cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Haemonetics Corp Net Cash Flow from Operations is projected to increase significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at 220.35 Million

Closer look at Haemonetics Standard Deviation

Haemonetics has current Standard Deviation of 2.37. The Standard Deviation is a measure of how spread out the prices or returns of an asset are on average. It is the most widely used risk indicator in the field of investing and finance. Standard Deviation is commonly used to measure confidence in statistical conclusions regarding certain equity instruments or portfolios of equities.

Standard deviation is applied to the annual rate of return of an investment to measure the investment's volatility. Standard deviation is also known as historical volatility and is used by investors as a gauge for the amount of expected market volatility. A large standard deviation usually indicates that the data points are far from the mean and a small standard deviation indicates that they are clustered closely around the mean.

Standard Deviation

SQRT(V)

2.37

SQRT	=	Square root notation
V	=	Variance of Haemonetics returns

Let's now compare Haemonetics Standard Deviation to its closest peers:

HAE

BAX

CMD

BDX

	HAE	2.37
	BAX	1.36
	CMD	3.66
	BDX	1.37

Will Haemonetics growth be viable after the surge?

Latest variance is at 5.61. Haemonetics currently demonstrates below-verage downside deviation. It has Information Ratio of 0.0 and Jensen Alpha of 0.17. However, we do advice investors to further question Haemonetics expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk.

Our Final Take On Haemonetics

Although other companies within the medical instruments & supplies industry are still a little expensive, even after the recent corrections, Haemonetics may offer a potential longer-term growth to shareholders. In closing, as of the 2nd of February 2021, our actual 30 days buy vs. sell advice on the firm is Cautious Hold. We believe Haemonetics is undervalued with low probability of distress for the next two years.

About Contributor

Achuva Shats is a Member of Macroaxs Editorial Board. Achuva writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Haemonetics Corp. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC

Haemonetics Story

USD 125.24 4.16 3.21%

How does Haemonetics Stands against Peers?

How Haemonetics utilizes its cash?

Closer look at Haemonetics Standard Deviation

Will Haemonetics growth be viable after the surge?

Our Final Take On Haemonetics

About Contributor

Would you like to provide feedback on the content of this article?

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY